We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Journal Scan / Research · December 05, 2020

Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma
JAMA 2020 Nov 17;324(19)1957-1969, SH AlDubayan, JR Conway, SY Camp, L Witkowski, E Kofman, B Reardon, S Han, N Moore, H Elmarakeby, K Salari, H Choudhry, AM Al-Rubaish, AA Al-Sulaiman, AK Al-Ali, A Taylor-Weiner, EM Van Allen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading